An autologous, genetically engineered anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are modified to express a CD19-specific CAR with CD28 costimulatory and CD3ζ signaling domains. Administered as a single infusion of CAR-positive viable T cells (target 2×10^6 cells/kg; maximum 2×10^8 cells). Upon CD19 engagement on B cells, CAR T cells activate cytotoxicity, proliferate, and release cytokines, leading to depletion of CD19+ lymphoma cells.